Table 1.
National antimicrobial consumption, expressed in DDD per 1000 inhabitants per day per antimicrobial class, for 2019 and 2020, Jordan.
| Antimicrobial Class | National Antibiotic Use 2019 | National Antibiotic Use 2020 | Relative Rate of Change * | ||
|---|---|---|---|---|---|
| Total DDD per 1000 Inhabitants per Day | Class% | Total DDD per 1000 Inhabitants per Day | Class% | ||
| Tetracyclines | 1.508 | 5.312% | 1.5673 | 5.844% | 1.10 |
| Penicillins with extended spectrum | 8.396 | 29.574% | 3.7361 | 13.930% | 0.47 |
| Beta-lactamase resistant penicillins | 0.002 | 0.008% | 0.0024 | 0.009% | 1.06 |
| Combinations of penicillins, including beta-lactamase inhibitors | 4.843 | 17.059% | 4.8462 | 18.069% | 1.06 |
| First-generation cephalosporins | 1.147 | 4.042% | 0.7015 | 2.616% | 0.65 |
| Second-generation cephalosporins | 2.650 | 9.335% | 2.5534 | 9.520% | 1.02 |
| Third-generation cephalosporins | 2.024 | 7.128% | 2.2750 | 8.482% | 1.19 |
| Fourth-generation cephalosporins | 0.000 | 0.001% | 0.0023 | 0.009% | 9.35 |
| Carbapenems | 0.043 | 0.152% | 0.0618 | 0.230% | 1.52 |
| Other cephalosporins and penems | 0.001 | 0.003% | 0.0003 | 0.001% | 0.34 |
| Combinations of sulfonamides and trimethoprim, including derivatives | 0.170 | 0.598% | 0.3646 | 1.359% | 2.27 |
| Macrolides | 3.238 | 11.405% | 4.8133 | 17.947% | 1.57 |
| Lincosamides | 0.714 | 2.514% | 1.3892 | 5.180% | 2.06 |
| Other aminoglycosides | 0.046 | 0.162% | 0.0425 | 0.158% | 0.98 |
| Fluoroquinolones | 2.745 | 9.669% | 3.0007 | 11.188% | 1.16 |
| Combinations of antibacterials | 0.416 | 1.464% | 0.5483 | 2.044% | 1.40 |
| Glycopeptide antibacterials | 0.046 | 0.162% | 0.0429 | 0.160% | 0.98 |
| Polymyxins | 0.003 | 0.010% | 0.0025 | 0.009% | 0.90 |
| Imidazole derivatives | 0.394 | 1.389% | 0.8657 | 3.228% | 2.32 |
| Other antibacterials | 0.004 | 0.013% | 0.0028 | 0.010% | 0.81 |
* Relative rate of change is calculated as (class% 2020/class% 2019).